Natera (NTRA) Launches Zenith Genomic Assay

Natera, Inc. (NASDAQ:NTRA) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. Natera (NTRA) Launches Zenith Genomic Assay On March 12, 2026, Natera, Inc. (NASDAQ:NTRA) announced the commercial launch of Zenith, a whole-genome sequencing assay engineered to significantly improve the diagnosis of rare genetic conditions. Zenith, with its genomic analysis, aims to shorten the diagnostic odyssey for the 30 million Americans affected by rare diseases. In its announcement, the ...